The US Food and Drug Administration (FDA) is requiring new safety changes
to the labels of all products containing estrogen alone or combined with progestin
for use by postmenopausal women, warning that the drugs may slightly increase
the risk of heart attack, stroke, breast cancer, and blood clots.
An estimated 10 million postmenopausal women in the United States currently
use estrogen-based hormone replacement therapy (HRT) to ease menopausal symptoms
and prevent osteoporosis, the agency said.
Stephenson J. FDA Orders Estrogen Safety Warnings. JAMA. 2003;289(5):537-538. doi:10.1001/jama.289.5.537